Nuvectis Pharma, Inc. (NVCT) Current Ratio
- Current ratio · latest quarter: Value 1.68×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.68× | Current assets / current liabilities. $22.38M ÷ $13.29M ≈ 1.68× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 22.38M USD | Assets, Current |
| Current obligations | 13.29M USD | Liabilities, Current |
| Cash and equivalents | 22.16M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 5.18M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $22.38M | $13.29M | $22.16M | (m) | (m) | (m) | $5.18M | (m) | 1.68× |
| 2026-03-31 | $25.40M | $11.18M | $25.13M | (m) | (m) | (m) | $4.70M | (m) | 2.27× |
| 2025-12-31 | $31.71M | $13.30M | $31.63M | (m) | (m) | (m) | $6.27M | (m) | 2.38× |
| 2025-09-30 | $35.59M | $11.58M | $35.44M | (m) | (m) | (m) | $6.44M | (m) | 3.07× |
| 2025-06-30 | $27.01M | $10.13M | $26.79M | (m) | (m) | (m) | $4.98M | (m) | 2.66× |
| 2025-03-31 | $30.15M | $9.19M | $29.86M | (m) | (m) | (m) | $2.99M | (m) | 3.28× |
| 2024-12-31 | $18.61M | $8.89M | $18.53M | (m) | (m) | (m) | $2.50M | (m) | 2.09× |
| 2024-09-30 | $17.31M | $6.32M | $17.17M | (m) | (m) | (m) | $2.26M | (m) | 2.74× |
| 2024-06-30 | $18.30M | $5.77M | $18.12M | (m) | (m) | (m) | $1.85M | (m) | 3.17× |
| 2024-03-31 | $19.71M | $5.69M | $19.46M | (m) | (m) | (m) | $1.76M | (m) | 3.46× |
| 2023-12-31 | $19.18M | $6.98M | $19.13M | (m) | (m) | (m) | $2.77M | (m) | 2.75× |
| 2023-09-30 | $22.26M | $5.58M | $22.06M | (m) | (m) | (m) | $3.49M | (m) | 3.99× |
| 2023-06-30 | $24.94M | $4.61M | $24.60M | (m) | (m) | (m) | $1.80M | (m) | 5.41× |
| 2023-03-31 | $16.21M | $3.93M | $15.47M | (m) | (m) | (m) | $2.10M | (m) | 4.12× |
| 2022-12-31 | $20.41M | $6.19M | $19.99M | (m) | (m) | (m) | $2.91M | (m) | 3.30× |
| 2022-09-30 | $24.87M | $4.49M | $23.64M | (m) | (m) | (m) | $2.25M | (m) | 5.54× |
| 2022-06-30 | $14.24M | $2.74M | $13.57M | (m) | (m) | (m) | $1.43M | (m) | 5.20× |
| 2022-03-31 | $17.62M | $3.06M | $16.69M | (m) | (m) | (m) | $1.35M | (m) | 5.76× |
| 2021-12-31 | $5.83M | $2.42M | $5.74M | (m) | (m) | (m) | $1.06M | (m) | 2.41× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |